These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 17155907)

  • 41. CpG oligodeoxynucleotide prolongs eosinophil survival through activation of contaminating B cells and plasmacytoid dendritic cells in vitro.
    Matsumoto K; Terakawa M; Fukuda S; Kato A; Toki S; Shinohara M; Wakiguchi H; Saito H
    Int Arch Allergy Immunol; 2006; 140 Suppl 1():42-50. PubMed ID: 16772726
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Increase in tumor size following intratumoral injection of immunostimulatory CpG-containing oligonucleotides in a rat glioma model.
    Ginzkey C; Eicker SO; Marget M; Krause J; Brecht S; Westphal M; Hugo HH; Mehdorn HM; Steinmann J; Hamel W
    Cancer Immunol Immunother; 2010 Apr; 59(4):541-51. PubMed ID: 19798500
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cytosine-phosphate-guanine motifs fail to promote T-helper type 1-polarized responses in human neonatal mononuclear cells.
    Prescott SL; Irwin S; Taylor A; Roper J; Dunstan J; Upham JW; Burgner D; Richmond P
    Clin Exp Allergy; 2005 Mar; 35(3):358-66. PubMed ID: 15784116
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Lipid-based delivery of CpG oligonucleotides enhances immunotherapeutic efficacy.
    Wilson KD; de Jong SD; Tam YK
    Adv Drug Deliv Rev; 2009 Mar; 61(3):233-42. PubMed ID: 19232375
    [TBL] [Abstract][Full Text] [Related]  

  • 45. CpG-ODN class C-mediated immunostimulation and its potential against Trypanosoma evansi in equines.
    Manuja A; Kumar P; Kumar R; Kumar B; Singha H; Sharma RK; Yadav SC
    Int Immunopharmacol; 2014 Oct; 22(2):366-70. PubMed ID: 25066759
    [TBL] [Abstract][Full Text] [Related]  

  • 46. CpG-Induced IFN-α production of plasmacytoid dendritic cells: time and dosage dependence and the effect of structural modifications to the CpG backbone.
    Jeske S; Pries R; Wollenberg B
    Nucleic Acid Ther; 2013 Apr; 23(2):118-24. PubMed ID: 23414178
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Impaired IFN-α secretion by plasmacytoid dendritic cells induced by TLR9 activation in chronic idiopathic urticaria.
    Futata E; Azor M; Dos Santos J; Maruta C; Sotto M; Guedes F; Rivitti E; Duarte A; Sato M
    Br J Dermatol; 2011 Jun; 164(6):1271-9. PubMed ID: 21198536
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide.
    Gürsel M; Verthelyi D; Gürsel I; Ishii KJ; Klinman DM
    J Leukoc Biol; 2002 May; 71(5):813-20. PubMed ID: 11994506
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-HBV effects of CpG oligodeoxynucleotide-activated peripheral blood mononuclear cells from patients with chronic hepatitis B.
    Li N; Fan XG; Chen ZH; Huang Y; Quan J; Liu ZB
    APMIS; 2005 Oct; 113(10):647-54. PubMed ID: 16309422
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of different classes of CpG-ODN in augmenting the generation of human epitope peptide-specific CTLs.
    Katsuda M; Iwahashi M; Matsuda K; Miyazawa M; Nakamori M; Nakamura M; Ojima T; Iida T; Hayata K; Yamaue H
    Int J Oncol; 2011 Nov; 39(5):1295-302. PubMed ID: 21805031
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CpG ODN mediated prevention from ovalbumin-induced anaphylaxis in mouse through B cell pathway.
    Xu W; Tamura T; Takatsu K
    Int Immunopharmacol; 2008 Feb; 8(2):351-61. PubMed ID: 18182251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level.
    Jurk M; Schulte B; Kritzler A; Noll B; Uhlmann E; Wader T; Schetter C; Krieg AM; Vollmer J
    Immunobiology; 2004; 209(1-2):141-54. PubMed ID: 15481148
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibitory effects of human immunodeficiency virus gp120 and Tat on CpG-A-induced inflammatory cytokines in plasmacytoid dendritic cells.
    Fang M; Xu N; Shao X; Yang J; Wu N; Yao H
    Acta Biochim Biophys Sin (Shanghai); 2012 Sep; 44(9):797-804. PubMed ID: 22814248
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Spontaneous formation of nucleic acid-based nanoparticles is responsible for high interferon-alpha induction by CpG-A in plasmacytoid dendritic cells.
    Kerkmann M; Costa LT; Richter C; Rothenfusser S; Battiany J; Hornung V; Johnson J; Englert S; Ketterer T; Heckl W; Thalhammer S; Endres S; Hartmann G
    J Biol Chem; 2005 Mar; 280(9):8086-93. PubMed ID: 15591070
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of intravenous and subcutaneous administration on the pharmacokinetics, biodistribution, cellular uptake and immunostimulatory activity of CpG ODN encapsulated in liposomal nanoparticles.
    Wilson KD; Raney SG; Sekirov L; Chikh G; deJong SD; Cullis PR; Tam YK
    Int Immunopharmacol; 2007 Aug; 7(8):1064-75. PubMed ID: 17570323
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Murine thymic plasmacytoid dendritic cells.
    Okada T; Lian ZX; Naiki M; Ansari AA; Ikehara S; Gershwin ME
    Eur J Immunol; 2003 Apr; 33(4):1012-9. PubMed ID: 12672067
    [TBL] [Abstract][Full Text] [Related]  

  • 57. CpG-ODN inhibits airway inflammation at effector phase through down-regulation of antigen-specific Th2-cell migration into lung.
    Ashino S; Wakita D; Zhang Y; Chamoto K; Kitamura H; Nishimura T
    Int Immunol; 2008 Feb; 20(2):259-66. PubMed ID: 18156622
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Co-stimulation with TLR3 and TLR21 ligands synergistically up-regulates Th1-cytokine IFN-γ and regulatory cytokine IL-10 expression in chicken monocytes.
    He H; Genovese KJ; Swaggerty CL; MacKinnon KM; Kogut MH
    Dev Comp Immunol; 2012 Apr; 36(4):756-60. PubMed ID: 22120532
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunostimulatory CpG oligonucleotides: Effect on gene expression and utility as vaccine adjuvants.
    Klinman DM; Klaschik S; Tomaru K; Shirota H; Tross D; Ikeuchi H
    Vaccine; 2010 Feb; 28(8):1919-23. PubMed ID: 20188247
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Monocytes are required for optimum in vitro stimulation of bovine peripheral blood mononuclear cells by non-methylated CpG motifs.
    Pontarollo RA; Rankin R; Babiuk LA; Godson DL; Griebel PJ; Hecker R; Krieg AM; van Drunen Littel-van den Hurk S
    Vet Immunol Immunopathol; 2002 Jan; 84(1-2):43-59. PubMed ID: 11825597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.